Oxford Immunotec Limited
91 Milton Park
Abingdon
Oxon
OX14 4RY
United Kingdom
Tel: 44-0-1235-442780
Fax: 44-0-1235-442781
Website: http://www.oxfordimmunotec.com/
Email: info@oxfordimmunotec.com
160 articles about Oxford Immunotec Limited
-
Oxford Immunotec Limited Announces Appointment of Richard Alteri as Chief Financial Officer
2/13/2012
-
Oxford Immunotec Limited Announces that the Centers for Centers for Medicare & Medicaid Services Increases Reimbursement for the T-SPOT®.TB Test CPT® Code 86481
1/9/2012
-
Oxford Immunotec Limited Release: Federal Supply Schedule (FSS) Contract Awarded to Oxford Diagnostic Laboratories® for T-SPOT®.TB Testing
11/7/2011
-
Oxford Immunotec Limited: Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost
6/27/2011
-
Oxford Immunotec Limited Release: Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost
6/27/2011
-
Tuberculosis Expert Joins Oxford Immunotec Limited as Senior Scientific Advisor
6/1/2011
-
Oxford Immunotec Limited: UK’s NICE Recommend Replacing Mantoux with TB Blood Tests for Key Patient Groups
3/25/2011
-
Oxford Immunotec Limited Release: UK's National Institute for Clinical Excellence (NICE) Recommend Replacing Mantoux with TB Blood Tests for Key Patient Groups
3/24/2011
-
Oxford Immunotec Limited Release: American Medical Association Establishes a New CPT(R) Code for Use with the T-SPOT(R).TB Test
12/20/2010
-
Oxford Immunotec Limited: Independent Peer-Reviewed Study Demonstrates That T-SPOT(R) TB Assay Outperforms Tuberculin Skin Test in Predicting Tuberculosis Disease
7/20/2010
-
Oxford Immunotec Limited: Independent Peer-Reviewed Study Demonstrates That T-SPOT(R).TB Assay Outperforms Tuberculin Skin Test in Predicting Tuberculosis Disease
7/19/2010
-
Oxford Immunotec Limited Release: The T-SPOT(R) TB Test Now Included in New Centers for Disease Control and Prevention (CDC) Guidelines1
6/28/2010
-
Oxford Immunotec Limited Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners
5/3/2010
-
Oxford Immunotec Limited Release: New Study Confirms 98.9% Specificity of Oxford Immunotec's T-SPOT(R)TB Assay
4/26/2010
-
Oxford Immunotec Limited Strengthens Leadership Team
1/7/2010
-
Oxford Immunotec Limited T-Spot(R). TB Gains FDA Premarket Approval
8/1/2008
-
Oxford Immunotec Limited Raises $40 Million
10/30/2007
-
Oxford Immunotec Limited Completes First Stage in 40 Million Funding Round
10/29/2007
-
Oxford Immunotec Limited Results Confirm Ability Of T-SPOT.TB To Detect Tuberculosis Disease In HIV Infected Patients
4/6/2006
-
Oxford Immunotec Limited Release: Study Results Demonstrate Accuracy Of T-Spot.Tb In Contact Tracing
1/24/2006